Loading
A phase 2/3 trial of Adagrasib, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Mirati Therapeutics Inc., now recruiting.
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 is a phase 2/3 interventional study registered as NCT04613596 by Mirati Therapeutics Inc., with 626 participants planned, started 2020-12-02 and due to reach its primary completion in 2028-10-31. Interventions recorded: Adagrasib, Adagrasib, Adagrasib, Adagrasib, Pembrolizumab. Conditions listed: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Bristol Myers Squibb.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Bristol Myers Squibb.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Pembrolizumab.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Bristol Myers Squibb.
Shares Adagrasib, KRAS & RAS inhibitors, Bristol Myers Squibb.
Shares Bristol Myers Squibb, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Pembrolizumab.
Shares Bristol Myers Squibb, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.